This month we’re highlighting one of the most commonly used mouse models to study Duchenne Muscular Dystrophy (DMD) – the MDX mouse model B10.mdx), and explore how our advanced services can support your efficacy studies in DMD. The X-linked muscular dystrophy (MDX)...
Last month, November, represented Pancreatic Cancer Awareness Month; a time to focus on the challenges posed by one of the most aggressive and lethal cancer types. Pancreatic cancer accounts for approximately 3% of all diagnosed cancers in Europe, with pancreatic...
In its role as an industry research partner, InnoSer is pleased to announce the successful completion of the CARDIOIDS project, a consortium-led initiative led by Professor Leon de Windt at Maastricht University. This project represents a major milestone in...
In ADPKD, mutations in the PKD1 or PKD2 gene cause changes in polycystin 1 or 2 (PC1 and PC2) expression, which in turn interferes with several intracellular signaling pathways that are e.g., involved in cell proliferation, fluid secretion, and ciliary function. The...
In a significant achievement, InnoSer has successfully validated tumorigenicity assay as part of the HEAL project, a major initiative aimed at accelerating the development of an allogeneic iPSC-based heart therapy. This milestone lays out the groundwork for safe and...
Immune Checkpoint Blockade in Oncology Drug Discovery In recent years, immune checkpoint blockade has emerged as a groundbreaking therapeutic strategy in immuno-oncology. Programmed cell death 1 receptor (PD-1), and its ligand programmed cell death ligand 1 (PD-L1)...
